The Art of Biomarker Validation

Developing safe and effective medications is no easy task. Every year, the pharma industry loses hundreds of billions of dollars due to safety-related attrition during the drug discovery process. For both patients and companies, improving R&D in this area could bring significant benefits. Now novel biomarkers designed to better detect and manage drug-induced organ injury – both preclinically and clinically – have been validated, and are ready to receive the regulatory stamp of approval.

In this issue:

• Malaria: After decades of research, a vaccine is rolled out in Africa
• Biomanufacturing: The power and promise of cell-free production systems
• Horizon Europe: The EC reduces bioeconomy to its agricultural aspects
• Biofairs Compass: The ultimate guide to leading Life Sciences Events in H2/2019